Back to Browse Journals » Clinical Ophthalmology » Volume 4

Considerations in glaucoma therapy: fixed combinations versus their component medications

Authors Eve J Higginbotham

Published Date December 2009 Volume 2010:4 Pages 1—9

DOI http://dx.doi.org/10.2147/OPTH.S6645

Published 16 December 2009

Eve J Higginbotham

Morehouse School of Medicine, Atlanta, GA, USA

Abstract: Fixed combinations of medications that lower intraocular pressure (IOP) are increasingly used in the treatment of glaucoma and ocular hypertension and offer several potential advantages over combined use of the separate component medications including enhanced convenience, improved adherence, reduced exposure to preservatives, and possible cost savings. This review aims to examine the current role of IOP-lowering fixed combinations in disease management. The results of studies that compared the efficacy and safety of IOP-lowering fixed combinations with their component medications are summarized, including those fixed combinations that consist of a prostaglandin analog and timolol. The fixed combinations currently available for use in the United States are fixed-combination dorzolamide/timolol (FCDT) and fixed-combination brimonidine/timolol (FCBT). Both of these fixed combinations reduce IOP more effectively than their component medications used separately as monotherapy. FCBT therapy also demonstrates a more favorable safety profile and reduced ocular allergy compared to monotherapy with brimonidine, a component medication. Few studies have directly compared the efficacy and safety of FCDT and FCBT, but available evidence suggests that FCBT is at least as effective as FCDT in lowering IOP and is more comfortable and better tolerated. Additional studies are needed to further evaluate the comparative efficacy and tolerability of FCDT and FCBT in the management of glaucoma and ocular hypertension.

Keywords: glaucoma, intraocular pressure, fixed combination, adherence, brimonidine

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo

Cai L, Wang X, Wang W, Qiu N, Wen J, Duan X, Li X, Chen X, Yang L, Qian Z, Wei Y, Chen L

International Journal of Nanomedicine 2012, 7:4499-4510

Published Date: 14 August 2012

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012

Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease

Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L

International Journal of General Medicine 2011, 4:639-646

Published Date: 6 September 2011

Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine

Duncan RS, Xin H, Goad DL, Chapman KD, Koulen P

Clinical Ophthalmology 2011, 5:543-548

Published Date: 26 April 2011

Budesonide/formoterol combination in COPD: a US perspective

Amir Sharafkhaneh, Amarbir S Mattewal, Vinu M Abraham, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:357-366

Published Date: 4 October 2010

Retinal vein occlusion: pathophysiology and treatment options

Niral Karia

Clinical Ophthalmology 2010, 4:809-816

Published Date: 16 July 2010

Epidemiology and burden of nasal congestion

Michael Stewart, BJ Ferguson, Len Fromer

International Journal of General Medicine 2010, 3:37-45

Published Date: 17 February 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Inflammatory mediators: Parallels between cancer biology and stem cell therapy

A Patel, Andrew C Heinrich, Bobby Y Reddy, Pranela Rameshwar

Journal of Inflammation Research 2009, 2:13-19

Published Date: 4 February 2009